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in early-stage chronic kidney disease (STOP-CKD):
study protocol for a randomized controlled
pilot trial
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Background: Chronic kidney disease is associated with increased arterial stiffness even in the early stages and this
is thought to be a key mediator in the pathophysiology of the increased cardiovascular risk associated with this
condition. The use of low-dose spironolactone has previously been shown to improve arterial stiffness and reduce
left ventricular mass safely in early-stage chronic kidney disease in the context of careful monitoring at a university
hospital. However, the majority of patients with chronic kidney disease are managed by their general practitioners
in the community. It is not known whether similar beneficial effects can be achieved safely using spironolactone in
the primary care setting. The aim of this study is to determine whether low-dose spironolactone can safely lower
arterial stiffness in patients with stage 3 chronic kidney disease in the primary care setting.
Methods/design: STOP-CKD is a multicentre, prospective, randomized, double-blind, placebo-controlled pilot
trial of 240 adult patients with stage 3 chronic kidney disease recruited from up to 20 general practices in South
Birmingham, England. Participants will be randomly allocated using a secured web-based computer randomization
system to receive either spironolactone 25 mg once daily or a matching inactive placebo for 40 weeks, followed by
a wash-out period of 6 weeks. Investigators, outcome assessors, data analysts and participants will all be blinded to
the treatment allocation. The primary endpoint is improved arterial stiffness, as measured by carotid-femoral pulse
wave velocity between baseline and 40 weeks. The secondary endpoints are incidence of hyperkalaemia, change in
estimated glomerular filtration rate, change in urine albumin:creatinine ratio, change in brachial blood pressure,
change in pulse waveform characteristics and overall tolerability of spironolactone. An additional quality control
study, aiming to compare the laboratory serum potassium results of samples processed via two methods (utilizing
routine transport or centrifugation on site before rapid transport to the laboratory) for 100 participants and a
qualitative research study exploring patients’ and general practitioners’ attitudes to research and the use of
spironolactone in chronic kidney disease in the community setting will be embedded in this pilot study.
Trial registration: Current Controlled Trials ISRCTN80658312.
Keywords: arterial stiffness, cardiovascular events, chronic kidney disease, feasibility, mineralocorticoid receptor
antagonist, pulse wave velocity, qualitative, randomized controlled trial, renal dysfunction, spironolactone* Correspondence: charles.ferro@uhb.nhs.uk
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Chronic kidney disease (CKD) is a long-term condition,
which has been described as the gradual and usually per-
manent loss of kidney function over time [1]. The glom-
erular filtration rate (GFR) has become the most accepted
test to assess kidney function and can be estimated using
several equations. One of the most widely used equations
to calculate and report estimated GFR (eGFR) was devel-
oped by the Modification of Diet in Renal Disease
(MDRD) study group using four variables: age, ethnicity,
sex and standardized serum creatinine levels calibrated to
an assay traceable to isotope-dilution mass spectrometry
[2]. This equation provides a measured eGFR of less than
90 ml/min per 1.73 m2 and allows reasonably accurate
GFR estimation in patients with CKD. Since the introduc-
tion of a clearer, multilayered definition of the CKD based
upon eGFR proposed by the National Kidney Foundation
Kidney Disease Outcome Quality Initiative in 2002, there
has been an increasing global awareness and recognition
of this important health condition [3]. The prevalence of
early CKD is increasing and now affects >13% of the
population of the developed world [4,5]. For an important
minority, CKD can progress to established renal failure
(ERF), requiring renal replacement therapy in the form of
either dialysis or transplantation [1]. The shift in focus for
health services to active early recognition and manage-
ment of chronic conditions has been a growing focus for
health services in recent years.
There is now convincing evidence confirming CKD as
an independent risk factor for cardiovascular (CV) mor-
bidity and mortality [4,6-8]. Although the cardiovascular
risk associated with ERF is substantial, the global health
burden of cardiovascular morbidity and mortality caused
by earlier stages of CKD may be much greater, given the
much higher prevalence of > 13% in developed countries
[3,9]. Patients with stage 3 CKD (an eGFR of 30 to
59 ml/min per 1.73 m2) represent the largest group, ac-
counting for about 8% of the adult population [9]. These
patients are mostly managed in the primary care setting
[10,11] and are far more likely to die from adverse car-
diovascular events than to progress to ERF [12]. Over a
one-year period (2009 to 2010), there were approxi-
mately 7,000 excess myocardial infarctions and 12,000
excess strokes in patients with CKD in England com-
pared with a non-CKD age- and sex-matched population
[13]. The cost of these excess cardiovascular events to
the UK National Health Service is estimated at £174 to
£178 million [13].
In addition to the conventional CV risk factors (that is,
hypertension, hypercholesterolaemia and smoking), other
risk factors including activation of the renin-angiotensin-
aldosterone system (RAAS), increased oxidative stress
or inflammation, proteinuria and mineral bone disorder
are also believed to be vital in contributing to the highCV burden in the CKD population [14,15]. Cardiovascular
disease in CKD differs from that of the general population
[14,15]. While vasculo-occlusive events, such as myocar-
dial infarction, are prevalent in CKD and remain one of
the important causes of death among the CKD population,
a greater proportion of cardiovascular deaths in CKD are
in fact attributable to sudden cardiac death, arrhythmia
and congestive heart failure [16]. There are two distinct
but overlapping arterial pathologies associated with CKD:
atherosclerosis and arteriosclerosis [17]. Atherosclerosis is
primarily an intimal disease characterized by patchy distri-
bution of fibro-atheromatous plaques, leading to vascular
occlusion. In contrast, arteriosclerosis is a diffuse disease
of the arterial medial layer associated with increased colla-
gen content, vascular calcification, hypertrophy and
hyperplasia of vascular smooth muscle cells, resulting
in thickening and hardening of the arteries [15]. Elastic
arteries are important to buffer the pressure oscillations
resulting from the intermittent ventricular ejection,
providing a ‘cushioning function’ to supply steady blood
flow to peripheral organs and tissues [18]. This loss of
arterial distensibility in CKD is believed to be a key mech-
anistic pathway that leads to myocardial hypertrophy and
fibrosis, systolic and diastolic cardiac dysfunction, in-
creased risk of stroke and progressive kidney disease due
to the exposure of increased systolic pressure and excessive
perfusion pressure fluctuations to the myocardial, cerebral
and renal microvasculature [15]. Notably, many of these
abnormalities are evident even in patients with early CKD
(stage 2 and 3) [19,20] despite satisfactory blood pressure
(BP) control [21].
Despite the heightened CV risk in patients with CKD,
there is a paucity of information to guide management
[22], with guidelines often based on post-hoc or sub-
group analyses of studies in the general population,
which might be prone to bias [23]. Applying treatment
strategies verified in the general population to patients
with CKD is a highly debatable approach for several rea-
sons, including the unique CV pathophysiology and risk
profile [24]. Because of their well-documented advan-
tages, randomized controlled trials (RCTs) represent the
gold standard for testing hypotheses in medical research
[25,26]. Studies in patients with CKD in the past have
often produced negative or neutral results, possibly be-
cause of several pivotal methodological flaws [27]. These
studies have often been underpowered as a consequence
of ‘over-optimistic’ assumptions about event rates and
the impact of therapeutic interventions. These factors
need to be taken into account when planning future tri-
als. Information gleaned from good quality, rigorously
conducted pilot studies is essential when designing large,
adequately powered hard-endpoint studies [28].
Thus far, the RAAS remains a major target for CV
intervention, and inhibitors of this system have been
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uria in patients with CKD [29-31]. In addition, retro-
spective analyses of the HOPE and PROGRESS data
[19,32] suggested that angiotensin-converting enzyme
inhibitors (ACEIs) might be even more effective in redu-
cing CV risk in patients with evidence of CKD than in
individuals with normal renal function. However pro-
longed use of ACEIs and angiotensin receptor blockers
(ARBs) can lead to aldosterone ‘breakthrough’ and their
efficacy in non-proteinuric CKD is less certain [29].
Aldosterone is a mineralocorticoid that is a key effector
of the RAAS. In vitro, it is implicated in numerous CV ef-
fects, including endothelial dysfunction, transmural arter-
ial inflammation, myocardial and vascular hypertrophy
and fibrosis independent of BP control [33-36]. In human
beings, a high aldosterone level is associated with higher
left ventricular mass, increased arterial stiffness, endothe-
lial dysfunction and insulin resistance [37]. The import-
ance of increased arterial stiffness in CKD is evidenced by
the strong independent association of this parameter with
mortality in patients with CKD [38,39]. Treatment with
mineralocorticoid receptor antagonists (MRAs) has been
proven to confer a powerful prognostic benefit in patients
with heart failure by the RALES and EPHESUS studies
[40,41] and was confirmed in a meta-analysis [42]. In
patients with CKD, MRAs are associated with significant
decreases in proteinuria [43,44]. Additionally, in a ran-
domized, double-blinded, placebo-controlled trial of 112
patients with stage 2 or 3 CKD in the secondary care set-
ting, Edwards et al. demonstrated that the addition of
spironolactone 25 mg once daily (a nonselective MRA) to
background ACEI or ARB treatment safely and effectively
reduced left ventricular mass (−14 ± 13 g versus +3 ± 11 g,
P < 0.01) and decreased arterial stiffness, as measured
by carotid-femoral pulse wave velocity (cfPWV: −0.8 ±
1.0 m/s versus −0.1 ± 0.9 m/s, P < 0.01), compared with
placebo [45-47]. A trial to examine whether these desir-
able intermediate endpoints changes can be translated
into long-term gains in terms of reduced CV morbidity
and mortality in large CKD cohort is clearly warranted.
However, the majority of patients with stage 3 CKD
in the UK [48] are managed in primary care by their
general practitioners (GPs) and are often older with less
well-defined renal phenotypes than the patients included
in the hospital-based study. Furthermore, concerns
among physicians about MRAs resulting in hyperkalae-
mia and worsened renal function, especially in the pri-
mary care setting, have also limited the widespread use
of spironolactone in patients with CKD. Hence, before
undertaking a large, expensive and appropriately pow-
ered definitive trial, this pilot study aims to carry out
preliminary development work for and to test the feasi-
bility of a RCT in the primary care setting. The primary
objective is to determine the effect of spironolactone onarterial stiffness in nondiabetic patients with stage 3
CKD managed in primary care. The secondary objectives
are to determine the safety of spironolactone in CKD
stage 3; examine whether the rate of hyperkalaemia is af-
fected by the method of laboratory analysis; assess the
effect of low-dose spironolactone on BP and albuminuria
in stage 3 CKD and qualitatively explore patients’ and
healthcare professionals’ attitudes towards research in
CKD and potential barriers to the use of spironolactone
in CKD in a community setting. Patients with diabetes
mellitus are excluded for a number of reasons. The
pathophysiology of arterial stiffness might be different,
with a greater importance of advanced glycation end-
products, for example [15]. Furthermore, vascular calci-
fication is more common and thus arterial stiffness may
be less likely to improve with spironolactone [15].
Hyperkalaemia is more common in patients with CKD
and diabetes than without; and this may be markedly
worsened by spironolactone. Diabetes would be ex-
pected to affect 20 to 30% of a community sample of
CKD, and hence would form a large subgroup within
the trial. Thus, although diabetes is an important issue
in CKD, this would be best explored in a separate study
concentrating on diabetes rather than affecting the risk:
benefit ratio of the proposed study in terms of reduced
chance of outcome and a greater number of adverse
events than expected.
Methods
Hypothesis
Low-dose spironolactone decreases arterial stiffness in
patients with stage 3 CKD. The objectives of the study
are detailed in Table 1.
Design
This is a multicentre, prospective, randomized, placebo-
controlled, double-blinded pilot trial in patients with
stage 3 CKD. Patients registered in participating primary
care practices within South Birmingham, England will
be screened with a view to recruiting 240 eligible partici-
pants. Potential participants will be identified by searching
computerized primary care clinical records for patients
with biochemical evidence of stage 3 CKD (defined as an
eGFR of 30 to 59 ml/min per 1.73 m2). The GFR will be
estimated by the four-variable MDRD formula with serum
creatinine recalibrated to be traceable to an isotope-
derived mass spectroscopy method [49]. Potentially eli-
gible patients will receive a patient information sheet
(Additional file 1) and be invited to attend a screening
visit at their own general practice, where the study will
be explained further. Written consent will be obtained
by the research team prior to enrolment into the study
(Additional file 2). Following the screening visit, all re-
cruited eligible, consenting participants will be randomized
Table 1 STOP-CKD study objectives
Pilot study To determine the recruitment rate and feasibility of the study
Quantitative arm Primary To determine the effect of spironolactone on arterial stiffness in patients with stage 3 CKD
Secondary To determine the safety of spironolactone in stage 3 CKD in a primary care setting, in regards
to the incidence of hyperkalaemia, worsened renal function and other adverse events
To assess the effect of spironolactone on blood pressure and albuminuria in stage 3 CKD
To assess the effect of spironolactone on pulse wave characteristics
Potassium substudy To examine whether the different methods of serum processing affect the rate of hyperkalaemia
seen in primary care
Qualitative arm To examine patients’ and healthcare professionals’ attitudes towards CKD and research in CKD in
the community setting
Explore patients’ and healthcare professionals’ attitudes towards the use of spironolactone in CKD
in a community setting and potential barriers to its use
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daily orally for 40 weeks. Participants will be followed up
during the duration of treatment and for 6 weeks after dis-
continuation of trial medication (wash-out period). The
total study duration is 46 weeks. The cfPWV will be mea-
sured using a Vicorder (Skidmore, Bristol, UK) system [50]
at baseline, week 40 and week 46 to detect any change in
arterial stiffness. Outcomes will be analyzed using an
intention-to-treat analysis.
Ethical approval has been received from the National
Research Ethics Service West Midlands Coventry and
Warwickshire (Reference No 12/WM/0168) and clinical
trial authorization has been granted by the Medicine
and Healthcare Products Regulatory Agency (MHRA)
(Reference No 21761/0274/001-0001). The research
team will seek further approval from the National Re-
search Ethics Service and the MHRA for any protocol
modifications. The sponsor, investigators, trial steering
committee (TSC), data management committee (DMC),
coordinating centre, recruiting sites, all members of the
study team and all trial participants will be informed of
the modifications.
The study will be coordinated by the Primary Care Clin-
ical Research and Trials Unit (PC-CRTU), which has been
fully accredited by the National Institute for Health Re-
search (NIHR) as a trials unit at the University of Birming-
ham according to the current guidelines for Good Clinical
Practice. The study will be monitored to confirm compli-
ance with the protocol and the protection of patients’
rights, as detailed in the Declaration of Helsinki. Informed
written consent will be obtained from all participants. The
inclusion criteria are that patients must be over 18 years
old and have stage 3 CKD. Patients will be excluded for
any of the following criteria:
 Diabetes mellitus,
 Terminal disease or considered otherwise unsuitable
by GP, Clinical diagnosis of chronic heart failure,
 Atrial fibrillation,
 Alcohol or drug abuse,
 Inability to comply with trial medication and
follow-up,
 Documented previous hyperkalaemia or intolerance
of spironolactone,
 Documented Addisonian crisis or taking
fludrocortisone,
 Severe hypertension: BP ≥ 180/110 mmHg,
 Systolic BP < 120 mmHg,
 Recent acute kidney injury or hospital admission
(within previous 6 weeks),
 Chronic diarrhoea,
 Urine albumin:creatinine ratio (uACR) ≥ 70 mg/mmol,
 Serum potassium ≥ 5 mEq/l on screening visit,
 Concomitant co-trimoxazole medication,
 Concomitant angiotensin-converting enzyme
inhibitor and angiotensin II receptor blocker
medication,
 Concomitant lithium medication,
 Concomitant warfarin medication,
 Pregnancy,
 Breastfeeding,
 Planned major surgical intervention within 46 weeks
of recruitment.
Study procedure
The study timeline and schedule of follow-ups and as-
sessments are summarized in Figure 1 and Table 2.
Screening visit
All consenting participants will attend a screening visit
during which the following will be carried out: (i) comple-
tion of a questionnaire regarding demographic details,
relevant medical history and concomitant medication; (ii)
BP measurement noninvasively using an automated
BpTRU machine (BPM-100, BpTRU™) [51]; (iii) blood and
Recruitment 
n=240
Screening visit
Randomisation visit
Week -2 
Week 0
Week 2 Treatment Group 
(Spironolactone 25mg OD)
n=120
Eligible participants
Placebo Group
(Placebo OD)
n=120
Week 2, 4, 8, 16, 28 follow up visits
Week 40 visit
Trial medication discontinued
6 weeks wash-out period
Week 46 visit
Week 40
Week 46
Trial closure
Data analysis and reporting
Figure 1 Study timeline.
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confirm the diagnosis of stage 3 CKD (two eGFR mea-
surements of 30 to 59 ml/min per 1.73 m2 at least 90 days
apart). A urine test will be used to exclude patients who
have a urine albumin:creatinine ratio (uACR) > 70 mg/mmol.
Participants with BP >140/90 mmHg and a uACR of 30
to 69 mg/mmol but not receiving either ACEI or ARB
will be referred to their GP to be considered for ACEI
or ARB treatment. They will be re-invited to the
screening visit after at least 6 weeks treatment with
ACEIs or ARBs.Table 2 Flowchart of assessment
Visit (week) Screenin
Valid informed consent gained √
Full demographic details √
Relevant medical history taken √
Concomitant medications √
Anthropometric measurements
Blood pressure measurement √
Pulse wave velocity and pulse waveform analysis measurement
Haematological and full biochemical profile √
Renal profile
Urine albumin:creatinine ratio √
EQ5D-5 L questionnaire
Medication monitoring questionnaire
EQ5D-5 L, European Quality of Life, 5 Dimensions, 5 Levels.Randomization visit
Eligible patients will then be invited back no later than
two weeks after their initial visit to attend a randomization
clinic. Informed consent will be sought again before
randomization to commence trial medication (Additional
file 3). Consenting participants will undergo the following
assessments: (i) EQ5D-5 L (European Quality of Life, 5
Dimensions, 5 Levels) [52] (quality of life survey) and
medication monitoring questionnaires (Additional file 4);
(ii) anthropometric measurements; (iii) BP measurement;
(iv) cfPWV measurement and pulse wave analysis (PWA).Treatment
g Randomization 2 4 8 16 28 40 46
√
√
√ √ √ √ √ √
√
√ √ √ √ √ √ √ √
√ √ √
√ √ √
√ √ √ √
√ √
√ √
√ √ √ √ √ √ √ √
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inactive placebo or spironolactone 25 mg once daily orally
for 40 weeks.
Follow-up visits
Following randomization, all participants will attend
follow-up visits at weeks 2, 4, 8, 16 and 28. The medica-
tion monitoring questionnaire will be filled in and bra-
chial BP measurements as well as blood samples to
monitor serum electrolytes and renal function will be
taken at each visit. Participants with a persistently ele-
vated BP of more than 150/90 mmHg will be referred to
their GP for BP management according to the guidelines
of the National Institute for Health and Care Excellence
[53]. Participants with hyperkalaemia or renal function
deterioration during the follow-up visits will be managed
according to the study protocol (Figure 2).
All measurements performed at the screening and
randomization visits will be repeated at 40 weeks after the
randomization, marking the end of the treatment phase.
All participants will discontinue the trial medication and≥ 30% increase of seru
≥ 25% decrease o
K+ ≥ 5.5 mEq/L
Repeat K+ level
No
No Yes
Continue with 
current dose of 
trial medication
5.5 ≤ K+ < 6.0 mEq/L
Recheck K+ as soon as possible at GP Researchto attend
Repeat
5.5 ≤ K+ < 6.0 mEq/L
Repeat 
K+ < 5.5 mEq/L
Continue with 
current dose of 
trial medication
Reduce trial medication to on
every other day.
Repeat K+  after 7 days.
Give advice on low potassium d
Figure 2 Study flowchart on management of renal dysfunction and h
potassium concentration.adherence will be assessed via pill count. After a wash-out
period of 6 weeks, all participants will attend final follow-
up visits (week 46 visit), whereby all measurements per-
formed at the week 40 visits will be repeated.
Study assessments
Blood pressure measurement
Blood pressure will be measured using the BpTRU™
BPM-100 automated blood pressure monitor [51]. Dur-
ing the screening visit, six serial sitting blood pressure
measurements will be taken simultaneously on both
arms, to identify which arm to use for BP monitoring for
all future visits. These six BP measurements will be per-
formed via the automated machine at 1 minute intervals.
Each BP reading will be recorded. The average BP read-
ing on each arm will be derived from the mean of the
second, third, fourth, fifth and sixth readings. If there
is >20 mmHg difference in systolic BP or >10 mmHg
difference in diastolic BP on the average BP reading be-
tween the arms, the arm with the higher reading will be
selected for all future BP and Vicorder measurements. Ifm creatinine from baseline 
OR
f eGFR from baseline
Stop trial medication immediately. 
Withdraw participant from study.
Urgent repeat blood test, renal 
ultrasound scan and review of 
participant by research clinician, 
Yes
K+ ≥ 6.0 mEq/L
 clinician to arrange participant 
 QEHB for urgent K+ recheck 
Repeat 
K+ ≥ 6.0 mEq/L
ce 
iet.
Stop trial medication 
immediately. 
Withdraw participant from 
study.
yperkalaemia. eGFR, estimated glomerular filtration rate; K+, serum
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arm. After measurement of sitting BP, postural BP will
be measured after asking the participant to stand up for
1 minute from sitting position. Postural hypotension is
defined as a drop of systolic BP >20 mmHg on standing.
Serial sitting BpTRU BP measurements and postural BP
will be repeated during each follow-up visit on weeks 2,
4, 8, 16, 28, 40 and 46.
Carotid-femoral pulse wave velocity and pulse wave
analysis measurement
The Vicorder system provides a noninvasive non-operator-
dependent method of obtaining cfPWV and PWA using a
volume displacement technique. Participants will be lying
supine at approximately 30° with the head and shoulders
supported by a pillow to prevent flexion of the neck.
The cfPWV and PWA measurements will be performed
on the same side as for BP for each participant after
5 minutes of rest.
Measurements will be obtained by placing a 100-mm-
wide BP cuff on the proximal thigh to measure the fem-
oral pulse and a 30-mm-wide partial cuff on the neck at
the level of the carotid artery. The distance between
the midclavicular point and the middle of the thigh
cuff will be measured and input to the Vicorder device
as aortic path length. The cuffs will each inflate to
60 mmHg and the corresponding oscillometric signal of
at least 14 s duration from each cuff will be digitally an-
alyzed to extract, in real time, the pulse waveforms,
pulse transit time and consequent cfPWV, which is a
measure of arterial stiffness. Pulse wave analysis will be
performed in a similar manner by placing the 100-mm-
wide BP cuffs on the selected arm and proximal thigh.
The cfPWV and PWA measurements will be performed
in triplicate. The mean value of the three recordings
will be used for subsequent analysis. Inconsistent values
among the three recordings will be further examined
by a designated senior investigator not involved in
taking the measurements, to determine the validity of
each measurement.
Randomization
Investigators, outcome assessors, data analysts and par-
ticipants will all be blinded to the treatment allocation
via the use of an apparently identical inert placebo and a
central automated allocation procedure. Participants will
be stratified by practice location, systolic BP (above or
below 140 mmHg) and urine albuminuria (uACR above
or below 30 mg/mmol) and assigned to either active
treatment or inactive placebo using a minimization algo-
rithm with a 70:30 weighted-coined approach if there is
an imbalance. Randomization assignment will be cen-
trally generated using the PC-CRTU secured web-based
randomization system.Unblinding
Researchers will be unblinded after the completion of
46 weeks follow-up of all subjects and closure of the
trial. The practice staff and all participants involved in
the study, including those who had withdrawn, will also
be informed of their trial medication allocation (spirono-
lactone or inactive placebo). During the trial, code
breaking will be avoided whenever possible. If emer-
gency unblinding is deemed to be appropriate, research
team members have access to break the randomization
code. When assessing severe adverse events, it will be
assumed that the participants receive spironolactone
(not inactive placebo). If the event is thought to be re-
lated and that the knowledge of treatment will alter the
medical management, unblinding will be performed via
the PC-CRTU secured web-based code-breaking system
with a paper-based code-breaking system back up.
Treatment
STOP-CKD is a double-blinded, placebo-controlled, ran-
domized trial involving two treatment arms: spironolac-
tone 25 mg orally once daily and inactive placebo orally
once daily. All participants will receive their allocated
trial medication for 40 weeks. The trial medication is
supplied by an authorized trial medication manufactur-
ing unit and funded via an NIHR Research for Patient
Benefit programme grant for this study. The trial medi-
cation was labelled and packaged by the trial medication
manufacturing unit prior to delivery to a designated
community pharmacy hub. The trial medication will
be dispensed at the pharmacy hub and delivered to the
local community pharmacy closest to the recruited gen-
eral practice for collection by the participants.
All participants will complete the medication moni-
toring questionnaire at each visit to record any side ef-
fect related to the trial medication and self-report trial
medication compliance during the 40 weeks treatment
phase. If participant’s serum potassium concentration is
5.5 to 5.9 mEq/l on repeat samplings, the trial medica-
tion will be reduced from once daily to once every
other day (see Figure 2).
Withdrawal criteria
Participants will be withdrawn from the trial if they
choose not to continue, if their GP considers that con-
tinued participation in the trial is inappropriate or if they
are no longer eligible according to the withdrawal cri-
teria listed in Table 3. Participants who withdraw from
the trial will be asked if they are willing to attend a final
research visit within 7 days of stopping the trial medica-
tion for blood and urine sampling, BP and Vicorder
measurement and completion of the EQ5D-5 L and
medication monitoring questionnaire. Data will be col-
lected for an intention-to-treat analysis.
Table 3 Withdrawal criteria
System Adverse effect Action
Blood pressure Hypotension Withdraw trial medication if systolic blood pressure <100 mmHg
or postural drop of systolic blood pressure >20 mmHg.
Metabolic Hyperkalaemia Withdraw trial medication if serum potassium≥ 6 mEq/l on
repeat sampling.
Hyponatraemia Withdraw trial medication if serum sodium <130 mEq/l on two
occasions.
Renal Renal dysfunction Withdraw trial medication if serum creatinine increment ≥30%
or eGFR reduction ≥25% from baseline.
Endocrine Men: gynaecomastia, impotence, diminished libido Withdraw trial medication if participant is intolerant of the side
effect or effects.
Women: hirsutism, oligomenorrhoea, amenorrhoea,
menorrhagia, breast tenderness
Nervous system Headache Withdraw trial medication if symptom persists for >1 week.
Confusion, ataxia, drowsiness Check postural blood pressure and serum sodium level. If
postural blood pressure and serum sodium levels are within
normal levels, but symptoms persist for >1 week, withdraw
trial medication.
Lethargy Withdraw trial medication if symptom persists for >1 week.
Dermatological Rash Withdraw trial medication.
Lichen planus, lupus-like syndrome Withdraw trial medication.
Hypersensitivity Anaphylaxis, contact dermatitis, eosinophilia Withdraw trial medication immediately.
Gastrointestinal General abdominal discomfort Withdraw trial medication if persistent discomfort for >1 week.
Diarrhoea or vomiting Withdraw trial medication if persistent diarrhoea or vomiting
for >3 days.
Gastric or duodenal ulcer or bleeding Withdraw trial medication.
Haematological Agranulocytosis Withdraw trial medication.
Hepatic Hepatotoxicity (alanine transferase > 123 U/l or
bilirubin > 44 μmol/l)
Withdraw trial medication.
Oncological Animal studies suggested association between
spironolactone with benign adenoma of the thyroid
and testes, malignant breast tumours, hepatocellular
carcinoma and leukemia
Withdraw trial medication.
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The primary endpoint of the study will be a change in
cfPWV between baseline and 40 weeks. Secondary end-
points are: (i) change in brachial BP; (ii) change in eGFR;
(iii) change in uACR; (iv) change in pulse waveform
characteristics; (v) incidence of hyperkalaemia; (vi) inci-
dence of renal dysfunction (increment of creatinine
≥30% or reduction of eGFR ≥25% from baseline); (vii)
incidence of other adverse events.
Sample size calculation and planned statistical analysis
In our recent study of the effect of spironolactone, the
Chronic Renal Impairment in Birmingham II (CRIB II)
study, the standard deviation of the change in cfPWV
was 1.0 m/s in the active treatment group and 0.9 m/s in
the control group. Hence, 100 subjects in each arm will
provide 90% power with an α value of 0.05 to demon-
strate a difference in change of cfPWV of 0.5 m/s be-
tween the active treatment and control groups. We aimto recruit 240 patients to account for an approximate
drop-out rate of 20%, which will result in at least 200 pa-
tients completing this randomized control trial, with 100 pa-
tients in each arm (inactive placebo versus spironolactone).
The difference in the primary outcome between experi-
mental conditions will be assessed using generalized
mixed models. Repeated measures within a subject will be
characterized as R side residual over-dispersion parame-
ters, accounting for baseline values. Frequency differences
will be tested using Fisher’s exact test. A prespecified mul-
tivariable analysis will examine the influence of change
in systolic BP and other relevant factors on changes in
the primary endpoint. Outcomes will be analyzed using
intention-to-treat analysis. A P value of less than 0.05 will
be considered statistically significant.
Data entry, coding, security, storage, access and quality
assurance will be managed according to PC-CRTU pol-
icy [54]. Study investigators will have access to the final
trial dataset.
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The STOP-CKD study will be coordinated by the PC-
CRTU at the University of Birmingham according to
the current guidelines for Good Clinical Practice. The
chief investigator takes overall responsibility for the
conduct of study. Any delegated or devolved responsi-
bility will be documented in a delegation log. An inves-
tigators group will meet monthly to provide oversight
of the developing trial, with more frequent operational
meeting of the chief investigator, trial manager and trial
team as required.
A TSC will be appointed and will provide overall super-
vision for the trial, in particular: trial progress, protocol
compliance, patient safety and review of updated infor-
mation. The TSC will include the trial management
group, two lay representatives and an independent chair
who has expertise relevant to the study. The TSC will
meet every 3 to 6 months, depending on the phase of
the study.
An independent DMC for the trial will be responsible
for the regular monitoring of trial data. The committee
will consist of an independent secondary care clinician,
an independent academic general practitioner and an in-
dependent statistician. The DMC will assess the progress
of the trial and give advice on whether the accumulated
data from the trial, together with the results from other
relevant trials, justifies the continuing recruitment of
further patients. The committee will meet in person or
by teleconference prior to the trial commencement and
then 3 and 6 months after initiation of the trial. The
DMC will make confidential recommendations to the
TSC as the decision-making committee for the trial
(Additional file 5).
Monitoring and safety assessments
Monitoring will be performed according to PC-CRTU
policy and be conducted centrally and at each local re-
cruitment sites. Any major problems identified during
monitoring will be reported to the TSC. All records will
be maintained in accordance with local regulations and
in a manner that ensures security and confidentiality. All
adverse events and severe adverse events will be re-
corded and followed up for the duration of the study or
until resolution. Assessment of adverse events will be
performed by the study investigators. All serious adverse
events will be graded and reported to the sponsor. Any
suspected unexpected serious adverse reactions will be
reported to the sponsor, ethics committee and MHRA.
Substudies
Quality control of laboratory tests
The time lapses from blood sampling to analysis of sample
in the biochemistry laboratory in the Queen Elizabeth
Hospital Birmingham will be recorded. At week 2, twoserum separator tube (SST) samples will be obtained from
up to 100 participants. One SST from each of the 100
participants will be centrifuged on site (at the recruited
general practice) before sending to the biochemistry la-
boratory at the Queen Elizabeth Hospital Birmingham for
potassium analysis. The other parallel SSTs from the same
participants will be sent via the routine specimens trans-
port from the general practices to the laboratory. The
serum potassium results from each pair of SSTs will be
compared to examine the influence of time delay during
routine general practice specimens’ transport on serum
potassium results.
Qualitative research study to address development and
feasibility issues
A qualitative research study will be embedded in this
pilot RCT to explore patients’ and GPs’ attitudes to
CKD, research in CKD and use of spironolactone in
CKD in the community setting, and to examine potential
barriers for research participation as well as barriers to
the use of spironolactone in the community. The out-
come of this qualitative study will help to indicate how
trial procedures might be modified for a future definitive
trial and improve our understanding of the factors that
might limit the prescription of spironolactone in com-
munity settings.
The data sampling technique includes a one-to-one
interview and a focus group. Interviews will be per-
formed at the beginning of the study with the aim of in-
volving both patients and GPs who have agreed or
declined to participate in the RCT. Focus groups will be
organized after participants have completed the RCT.
General practitioners and patients will receive patient in-
formation sheets on the qualitative study. Informed writ-
ten consent will be obtained prior to participation in the
qualitative research.
A grounded theory approach [55] will be used to guide
sampling, data collection and analysis. Purposive sam-
pling will allow for maximum variety of patient and GP
characteristics. Up to 30 patients and 30 GPs will be se-
lected for interview. Up to four focus groups will be or-
ganized among participating patients and GPs. Patient
sampling will ensure representation of views from par-
ticipants of different age, ethnicity, socio-economic sta-
tus and sex. General practitioner sampling will ensure
representation of different ages of GP, practice locations
and practice sizes. Interviewing will continue until data
saturation has been achieved. The interviews will be
confidential and face-to-face using a topic prompt,
which will be refined over the course of the initial inter-
views [56]. They will be undertaken by a research fellow,
supervised by an experienced qualitative researcher.
Both the interviews and focus group meetings will be
carried out in a place convenient to the interviewees.
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and transcribed verbatim. Transcriptions will be read
and checked for accuracy by the researcher and the text
entered into a computerized database using the NVivo
(QSR International) qualitative software package [57].
Constant comparative analysis [55] will be used to inter-
pret the data. Data collection and analysis will be itera-
tive, with new data being used to confirm or challenge
emerging concepts.
Discussion
The deleterious effects of excessive aldosterone activa-
tion are well-established and known to promote adverse
metabolic effects, vasoconstriction, inflammation and
fibrosis, which ultimately lead to significant CV and
renal damage. Substantial improvement of CV function
and structure with the use of spironolactone in the
RCT of Edwards et al. [45-47] has further demon-
strated the potential of aldosterone inhibition as a
powerful CV treatment for the CKD population. If the
use of low-dose spironolactone is proven to achieve
similar safety and desirable effects on arterial stiffness
in the CKD population managed in primary care in this
pilot study, it will undoubtedly facilitate the develop-
ment of a future definitive large RCT to determine the
effect of spironolactone on decisive hard-endpoints
(CV morbidity and mortality).
Trial status
Upon submission, the STOP-CKD study is in the
process of patient recruitment.
Protocol amendments
Version 1.0 approved on 22 March 2012.
Version 2.0 approved on 18 June 2012.
Version 3.0 approved on 26 July 2012.
Version 4.0 approved on 20 June 2013.
Dissemination policy
We would anticipate publishing the overall findings of
this study in peer-reviewed journals and disseminate the
results to all trial participants. All publications and pre-
sentations relating to the trial will be authorized by the
TSC and authorship eligibility will be applied according
to the guidelines of the International Committee of
Medical Journal Editors. No use of professional writers
is intended.
Additional files
Additional file 1: Patient information sheet, version 2.2.
Additional file 2: Consent form, part 1, version 2.2.
Additional file 3: Consent form, part 2, version 2.2.Additional file 4: Medication monitoring questionnaire.
Additional file 5: Data monitoring committee charter.
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